ES2026184T3 - Procedimiento para preparar una solucion acuosa esteril. - Google Patents

Procedimiento para preparar una solucion acuosa esteril.

Info

Publication number
ES2026184T3
ES2026184T3 ES198787306297T ES87306297T ES2026184T3 ES 2026184 T3 ES2026184 T3 ES 2026184T3 ES 198787306297 T ES198787306297 T ES 198787306297T ES 87306297 T ES87306297 T ES 87306297T ES 2026184 T3 ES2026184 T3 ES 2026184T3
Authority
ES
Spain
Prior art keywords
aqueous solution
preparing
procedure
sterile aqueous
taurultam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787306297T
Other languages
English (en)
Inventor
Rolf Wilhelm Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Application granted granted Critical
Publication of ES2026184T3 publication Critical patent/ES2026184T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA SOLUCION ACUOSA QUE CONTIENE UNA CONCENTRACION BACTERIALMENTE EFICAZ DE TAUROLIDINA Y/O TAURULTAM JUNTO CON UN POLIOL PARENTERALMENTE ACEPTABLE. LA SOLUCION ACUOSA ES PARTICULARMENTE ADECUADA PARA LA ADMINISTRACION PARENTERAL.
ES198787306297T 1986-07-17 1987-07-16 Procedimiento para preparar una solucion acuosa esteril. Expired - Lifetime ES2026184T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868617482A GB8617482D0 (en) 1986-07-17 1986-07-17 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2026184T3 true ES2026184T3 (es) 1992-04-16

Family

ID=10601226

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787306297T Expired - Lifetime ES2026184T3 (es) 1986-07-17 1987-07-16 Procedimiento para preparar una solucion acuosa esteril.

Country Status (9)

Country Link
EP (1) EP0253662B1 (es)
JP (1) JP2550356B2 (es)
KR (1) KR950009096B1 (es)
AT (1) ATE58294T1 (es)
AU (1) AU604031B2 (es)
CA (1) CA1287300C (es)
DE (1) DE3766175D1 (es)
ES (1) ES2026184T3 (es)
GB (1) GB8617482D0 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614170B2 (en) * 1988-08-26 1991-08-22 Minnesota Mining And Manufacturing Company A steam sensitive composition and a sterilization indicator composition containing the same
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
ATE555780T1 (de) * 1997-10-24 2012-05-15 John P Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
FR2771928B1 (fr) * 1997-12-05 2001-04-13 Jean Noel Thorel Composition comprenant des derives de taurine ; son utilisation comme agent conservateur d'un produit alimentaire, ou pharmaceutique, topique ou cosmetique
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
CN100519525C (zh) 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
CA2393252A1 (en) 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors
CA2462564C (en) 2001-10-01 2012-07-10 Rhode Island Hospital Methods of inhibiting metastases
EP3028705A1 (en) 2006-09-07 2016-06-08 Ed. Geistlich Söhne Ag Für Chemische Industrie Treating bone cancer
WO2013190355A1 (en) 2012-06-18 2013-12-27 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP6746605B2 (ja) 2014-12-19 2020-08-26 ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ オキサチアジン様化合物を作製する方法
JP6933659B2 (ja) 2016-03-18 2021-09-08 ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ トリプルネガティブ乳癌の治療方法
IL307990A (en) 2021-04-29 2023-12-01 Geistlich Pharma Ag Antimicrobial and anticancer agents
WO2024028846A1 (en) 2022-08-05 2024-02-08 Geistlich Pharma Ag Combination therapy for treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600878A5 (es) * 1975-04-28 1978-06-30 Gaba Ag
DE2731013C2 (de) * 1977-07-08 1982-07-15 Lentia Gmbh Verfahren zur Herstellung einer wäßrigen Infusionslösung
US4296130A (en) * 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
JPS58116413A (ja) * 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd 静注用総合ビタミン剤
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
JPS60246313A (ja) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンの注射剤およびその製法

Also Published As

Publication number Publication date
JPS6372626A (ja) 1988-04-02
ATE58294T1 (de) 1990-11-15
KR950009096B1 (ko) 1995-08-14
AU604031B2 (en) 1990-12-06
EP0253662B1 (en) 1990-11-14
KR880001283A (ko) 1988-04-22
CA1287300C (en) 1991-08-06
AU7578587A (en) 1988-01-21
GB8617482D0 (en) 1986-08-28
DE3766175D1 (de) 1990-12-20
JP2550356B2 (ja) 1996-11-06
EP0253662A1 (en) 1988-01-20

Similar Documents

Publication Publication Date Title
ES2026184T3 (es) Procedimiento para preparar una solucion acuosa esteril.
DE69129921T2 (de) Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten
DK543587D0 (da) Farmaceutisk praeparat stabiliseret mod oxidation
ATE77755T1 (de) Kontrastmittel mit stabilen, freien radikalen.
DE3772001D1 (de) Stabilisierte arzneimittelzubereitungen.
DK84088A (da) Naphthalenderivater med anvendelse som antiallergiske og antiinflammatoriske midler
ATE43789T1 (de) Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
DE69424147D1 (de) Vorrichtung für die vaginale Verabreichung von Tamoxifen und dessen Analogen
DE69032000T2 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
NO950360D0 (no) Nytt legemiddel som inneholder 3-fenylsulfonyl-3,7-diazabisyklo[3,3,1Ånonan-forbindelser
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
DE59005355D1 (de) Dialysier- und Spüllösung zur intraperitonealen Verarbreichung.
HU911922D0 (en) New medical preparations containing 3,7-diazabicyclo(3.3.1)nonane compounds
SE8601963L (sv) O-sulfaterade beta-laktamhydroxamsyror
ES8302680A1 (es) "un procedimiento para sintetizar 3(4-fenil-1-piperacinio-1-il)-1,2-propandiol 3(teofilin-7-il)-1-propansulfonato"
DE68907845T2 (de) Verbrückte bicyclische 4-(4-(3-Benzisothiazolyl)-1-piperazinyl)-butylimide mit antipsychotischer Wirkung.
RO95059A (ro) Procedeu pentru prepararea unor cicloalcancarboxanilide
DE3778925D1 (de) Hydroxamsaeure von 7-oxabicycloheptan substituierten aethern.
ES8609289A1 (es) Un procedimiento para preparar nuevos derivados de benzotiazina.
AU604094C (en) Stable, injectable solutions of vinca dimer salts
SU1351063A1 (ru) Производные 2-тиазолзамещенного 5-нитрофурана, проявляющие антистафилококковую активность
DE3472951D1 (en) P-alkyl or cycloalkyl phenoxy alkanols and alkanol esters and use for the treatment of allergic conditions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 253662

Country of ref document: ES